Received: 25 October 2020
Accepted: 22 February 2021
First Online: 6 March 2021
: Ethics approval and consent to participate are detailed in the “InternalRef removed” section. After providing their written informed consent, patients were prospectively included in the ethics committee-approved ALCINA study (NCT02866149). Eligibility criteria were patients aged > 18 years with ER+ HER2− MBC, treated at Institut Curie with endocrine therapy (AI or fulvestrant) and palbociclib.
: Not applicable.
: FC Bidard received research support and consulting fees from Pfizer, Novartis, and Lilly, unrelated to this study. The other authors have no disclosure.